Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term facilitated access study of SBR759 in chronic kidney disease patients with hyperphosphataemia
2009-011007-23Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SBR759 in hyperphosphatemia and chronic kidney disease (CKD), sponsored by Novartis. Primary endpoint: Long-term safety of SBR759. Started Jul 2009; status: terminated.
02
Drugs
SBR759
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-011007-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011007-23.